Ipamorelin peptide is a selective growth hormone secretagogue — it prompts your pituitary to release growth hormone without spiking cortisol or appetite. TelosRX evaluates ipamorelin protocols asynchronously; access requires a provider-issued prescription and individual health review.
If you're looking at growth hormone peptides for recovery, fat loss, or sleep quality, ipamorelin comes up early in the research. Here's what the science actually shows, what it doesn't, and what clinical dosing looks like.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide — five amino acids — that mimics ghrelin and binds to the growth hormone secretagogue receptor (GHSR-1a) in the pituitary gland. Binding this receptor triggers a pulse of growth hormone release.
It was characterized in a foundational 1998 study by Raun and colleagues in the European Journal of Endocrinology as the first "selective" growth hormone secretagogue — meaning it triggered GH release without significantly affecting cortisol, ACTH, or prolactin at therapeutic doses.
Ipamorelin is not FDA-approved. It is available as a compounded peptide through licensed telehealth providers, prepared under federal compounding regulations and subject to evaluation by a licensed provider before any prescription can be issued.
How Ipamorelin Works: The GHSR-1a Mechanism
Most growth hormone-releasing peptides (GHRPs) stimulate the GHSR-1a receptor. But older GHRPs — GHRP-2 and GHRP-6 — also trigger releases of cortisol and prolactin, and GHRP-6 in particular stimulates appetite through ghrelin-like activity.
Ipamorelin's selectivity is its defining feature. It produces a discrete GH pulse — typically lasting 2–3 hours — without the cortisol spike or appetite stimulation of older compounds.
It also doesn't suppress the body's own GH production the way synthetic GH can. Ipamorelin works with the pituitary feedback system rather than replacing it — preserving the natural pulsatile GH pattern over time.
What Research Shows About Ipamorelin's Benefits
Most published ipamorelin research is preclinical — animal models and in vitro studies. Human clinical trial data is limited. The table below frames each benefit area by its evidence type so you know what you're looking at.
| Benefit Area | Evidence Type | What Research Shows |
|---|---|---|
| GH pulse stimulation | Animal studies + early human pharmacokinetic data | Reliable GH pulses at 200–300 mcg doses; pulse duration approximately 2–3 hours |
| Body composition | Preclinical (animal) | Animal models showed reductions in body fat and increases in lean mass; no large human RCTs confirmed |
| Bone density | Preclinical (animal) | Studies in pigs showed improved bone mineral density with extended ipamorelin use; human data not established |
| Sleep quality | Indirect / GH class effect | GH secretion peaks during deep sleep; peptides that amplify nocturnal GH pulses are theorized to improve sleep architecture — not specifically confirmed in ipamorelin human RCTs |
| Recovery and healing | GH class-level evidence | GH plays a documented role in tissue repair; no ipamorelin-specific human recovery RCTs exist |
| Cortisol and prolactin selectivity | Human pharmacokinetic data (Raun et al., 1998) | No significant cortisol or ACTH elevation at therapeutic doses — the defining selective advantage over older GHRPs |
For context on how ipamorelin fits into a GH stack, see our guide on CJC-1295 and ipamorelin combined protocols.
Ipamorelin Dosage: What Clinical Protocols Use
There is no FDA-approved dosing standard for ipamorelin. Clinical use through licensed providers is based on pharmacokinetic data, not formal drug labeling. Any dosing must come from a licensed provider after individual evaluation — not from a general guide.
- Typical dose range: 200–300 mcg per subcutaneous injection, subject to provider guidance
- Frequency: Once to three times daily; nocturnal dosing before sleep is common, aligning with the body's natural GH pulse
- Route: Subcutaneous injection
- Protocol length: Varies by provider — some use 8–12-week cycles with breaks; others use continuous low-dose approaches based on lab monitoring
These figures are informational only. Dosing for any individual is subject to medical approval by a licensed provider based on health history, labs, and clinical presentation.
Ipamorelin Side Effects and Safety
Ipamorelin has a favorable safety profile relative to older GHRPs, based on available data. Commonly reported side effects in clinical use:
- Mild injection-site redness or irritation
- Transient headache or flushing (most common during early titration)
- Mild water retention at higher doses
- Brief lightheadedness immediately post-injection
What ipamorelin typically does NOT cause at therapeutic doses: the cortisol spike seen with GHRP-2, or the significant appetite stimulation of GHRP-6. Long-term human safety data for extended ipamorelin use is limited — most published data covers weeks to months of use in small cohorts.
Ipamorelin vs Other GH Peptides
| Peptide | Receptor Target | GH Selectivity | Cortisol Effect | Appetite Effect | Common Use Case |
|---|---|---|---|---|---|
| Ipamorelin | GHSR-1a (ghrelin receptor) | High | Minimal | Minimal | Recovery, body comp, sleep |
| GHRP-2 | GHSR-1a | Moderate | Moderate increase | Moderate | GH stimulation |
| GHRP-6 | GHSR-1a | Moderate | Moderate increase | High | GH stimulation, appetite |
| CJC-1295 | GHRH receptor | High | Minimal | Minimal | GH pulse extension (stacked with ipamorelin) |
| Sermorelin | GHRH receptor | High | Minimal | Minimal | Anti-aging, sleep quality |
| MK-677 (Ibutamoren) | GHSR-1a (oral) | Moderate | Mild increase | Significant | GH stimulation via oral route |
For more on sermorelin as a GHRH-receptor alternative, see our sermorelin research guide. For MK-677, see our MK-677 overview.
Considering a GH peptide protocol? TelosRX evaluates requests asynchronously — you complete your health intake on your own schedule, a licensed provider reviews your labs and history, and if appropriate, a prescription is issued. No live appointment required. Start your private evaluation at TelosRX.
Who Considers Ipamorelin?
Based on how licensed providers structure GH peptide evaluations, ipamorelin tends to be considered for adults focused on:
- Recovery support after intense training or injury
- Age-related decline in GH output (GH production declines approximately 14% per decade after early adulthood)
- Sleep quality as part of a longevity or optimization protocol
- Body composition goals alongside consistent resistance training
It is not appropriate for everyone. Contraindications, interactions, and individual health context are all evaluated by the licensed provider before a prescription is issued. Ipamorelin is not FDA-approved and is not indicated for treating or preventing any disease.
For a research summary on GH peptides and what published data supports, examine.com's ipamorelin entry is a useful starting point.
Frequently Asked Questions
What does ipamorelin peptide do?
Ipamorelin binds to the growth hormone secretagogue receptor (GHSR-1a) in the pituitary and triggers a pulse of growth hormone release. Unlike older GHRPs, it does this without significantly raising cortisol, prolactin, or appetite. The resulting GH pulse is thought to support recovery, body composition, and sleep quality, based primarily on preclinical research and GH class-level evidence.
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved as a drug. It is available as a compounded peptide through licensed telehealth providers and compound pharmacies, prepared under federal compounding regulations. Any use requires evaluation and a provider-issued prescription from a licensed provider before access.
How long does it take to see results from ipamorelin?
Based on clinical observations and GH pharmacokinetics, noticeable changes in sleep quality may occur within 2–4 weeks for some individuals, while body composition and recovery changes typically take 8–12 weeks of consistent use. Individual response varies significantly. There are no published human RCTs establishing a precise timeline for ipamorelin-specific outcomes.
Can I stack ipamorelin with CJC-1295?
Yes — the CJC-1295 and ipamorelin combination is one of the most commonly used GH peptide stacks. CJC-1295 is a GHRH analog that extends the GH pulse duration; ipamorelin triggers the pulse itself. Together they produce a more sustained GH elevation than either alone. This combination requires provider evaluation and prescription and is not FDA-approved.
Does ipamorelin affect testosterone levels?
Ipamorelin does not directly stimulate testosterone production — it targets the growth hormone axis, not the hypothalamic-pituitary-gonadal axis. Some indirect effects on body composition may support testosterone levels over time, but ipamorelin is not a testosterone therapy and shouldn't be used with that as a primary goal.
What is the typical ipamorelin dosage?
Protocols in licensed clinical settings typically range from 200 to 300 mcg per subcutaneous injection, one to three times daily, with nocturnal dosing common to align with the body's natural GH pulse. This is not a universally approved dose — it must be determined by a licensed provider based on individual health assessment and is subject to medical approval.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.